Roles of inflammatory cell infiltrate in periprosthetic osteolysis

Front Immunol. 2023 Dec 1:14:1310262. doi: 10.3389/fimmu.2023.1310262. eCollection 2023.

Abstract

Classically, particle-induced periprosthetic osteolysis at the implant-bone interface has explained the aseptic loosening of joint replacement. This response is preceded by triggering both the innate and acquired immune response with subsequent activation of osteoclasts, the bone-resorbing cells. Although particle-induced periprosthetic osteolysis has been considered a foreign body chronic inflammation mediated by myelomonocytic-derived cells, current reports describe wide heterogeneous inflammatory cells infiltrating the periprosthetic tissues. This review aims to discuss the role of those non-myelomonocytic cells in periprosthetic tissues exposed to wear particles by showing original data. Specifically, we discuss the role of T cells (CD3+, CD4+, and CD8+) and B cells (CD20+) coexisting with CD68+/TRAP- multinucleated giant cells associated with both polyethylene and metallic particles infiltrating retrieved periprosthetic membranes. This review contributes valuable insight to support the complex cell and molecular mechanisms behind the aseptic loosening theories of orthopedic implants.

Keywords: aseptic loosening; inflammation; innate immune system; macrophage; osteoclast; osteoimmunology; periprosthetic osteolysis; total joint replacement.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Inflammation / metabolism
  • Joint Prosthesis* / adverse effects
  • Osteoclasts / metabolism
  • Osteolysis* / metabolism
  • Polyethylene / adverse effects
  • Polyethylene / metabolism

Substances

  • Polyethylene

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was financially supported by Agencia Nacional de Investigación y Desarrollo (ANID) of Chile grants: Fondecyt Inicio N°11190536 - Basal funding for Scientific and Technological Center of Excellence, IMPACT, #FB210024. IP-T is supported by the Region des Pays de la Loire (France) and the Institut of Cancérologie de l’Ouest (Saint-Herblain, France).